Articles tagged with Tlr Signaling
Researchers from the University of Bonn have developed a new method to study immune receptors using a label-free biosensor assay. This approach allows for the detection of specific chemical signals that activate Toll-like receptors (TLRs), which are found on the surface of immune cells and play a crucial role in detecting infections. T...
A new therapeutic approach combining cognitive behavioral therapy (CBT) and lucid dreaming has shown promise in reducing nightmare severity and frequency in patients with narcolepsy. The study, published in the Journal of Sleep Research, found overall reductions in nightmare symptoms in all six participants tested.
Researchers discovered a unique probiotic strain, Bifidobacterium bifidum BB1, that strengthens intestinal barrier function and protects against harmful bacteria. This strain may lead to the development of novel therapies for patients with inflammatory bowel disease and other inflammatory conditions.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
Researchers found that a molecule associated with the X chromosome contributes to lupus development in females. The X-inactive specific transcript (XIST) triggers an immune response that damages healthy tissue, leading to muscle and joint pain, skin rashes, and other complications.
A recent study found elevated TonEBP expression in patients with lupus nephritis, correlating with inflammatory cytokines and kidney damage. Suppressing TonEBP was shown to halt lupus progression and mitigate kidney damage in animal models.
Researchers identified toll-like receptor (TLR) signaling as a novel pathway regulating GLI3 expression, which plays a role in inflammatory cytokine production and cancer. They found that IRF3 directly binds to the GLI3 promoter region, increasing its expression upon TLR4 stimulation.
Researchers at the Salk Institute have discovered a molecular pathway that regulates immune inflammation, known as the TAM receptor tyrosine kinase. The study found that activating this pathway can help control chronic autoimmune diseases such as lupus and rheumatoid arthritis by inhibiting an out-of-control inflammatory response.
Researchers find biglycan acts as endogenous ligand of Toll-like receptor 4 in macrophages, increasing responses and leading to improved survival in sepsis. Mice lacking biglycan show increased survival benefit, highlighting the protein's pro-inflammatory role.